Researchers have restored light perception in blind animals using an unlikely tool: light-activated eye drops — and without gene therapy, implants, or surgery.
A team led by the Institute for Bioengineering of Catalonia (IBEC), with principal investigator Pau Gorostiza, developed compounds called prosthe6 that use photopharmacology — molecules carrying a light-sensitive switch that changes their activity when illuminated. The compounds target ON-bipolar neurons and mGlu6 proteins in the retina, effectively substituting for lost photoreceptors and reactivating the eye’s surviving circuitry. The work was published in the Journal of the American Chemical Society.
What it did
The approach restored saccadic eye movements in blinded zebrafish larvae and light-avoidance behavior in blind mice, and it worked under normal indoor and outdoor lighting — after either injection or topical eye-drop application. It targets diseases that destroy photoreceptors, including age-related macular degeneration and retinitis pigmentosa, which together affect roughly 200 million people worldwide.
Why it matters — and the caveat
“Our goal was to restore vision using a molecular mechanism that is as close as possible to how the healthy retina works,” said co-first author Rosalba Sortino. Because it works on existing retinal cells with a simple drop — no gene editing or hardware — it could be simpler to deliver than many vision therapies. But this is animal research; a spinout (Eyelumina) is working toward clinical trials, so human use remains to be proven.